Filing summary
Entity clarification: Although the request identifies MoonLake Immunotherapeutics, this 10-Q is filed by Helix Acquisition Corp., a blank-check company that had not yet completed its proposed combination with MoonLake. It reports the quarter ended September 30, 2021; the financial statements are unaudited.
Business context and financial results
Helix had no operating business or revenue during the period. Its activities were searching for a business combination and covering public-company and transaction-related costs. Accordingly, operating margins are not meaningful.
- Three months ended September 30, 2021: General and administrative expenses were $2.094 million; trust-account interest income was $1,481; net loss was $2.092 million.
- Nine months ended September 30, 2021: General and administrative expenses were $2.346 million; trust-account interest income was $25,436; net loss was $2.321 million. Basic and diluted loss per share were $0.16 for both Class A and Class B shares.
- Prior-period comparison: The comparable income statement period provided is August 13, 2020 (inception) through September 30, 2020, when net loss was $5,000. This is not a comparable full-quarter or nine-month operating period.
Financial position, cash flow, and liquidity
- At September 30, 2021, cash outside the trust was $1.029 million, and trust-account investments were $115.040 million. Total assets were $116.247 million.
- Current liabilities were $2.059 million, including accrued expenses; the company also reported a $4.025 million deferred underwriting fee payable, due only if a business combination closes. No working-capital loans were outstanding. Management reported a working-capital deficit of approximately $0.9 million.
- Nine-month cash used in operating activities was $249,109; cash used in financing activities was $58,063, reflecting repayment of a related-party note. Cash decreased by $307,172 to $1.029 million.
- Compared with December 31, 2020, cash declined from $1.336 million, accrued expenses rose from $67,120 to $2.059 million, and the trust balance increased from $115.015 million to $115.040 million.
Material changes, transaction, and outlook
- The filing reports that Helix revised its presentation of redeemable public shares: all 11.5 million Class A public shares are classified as temporary equity at $115 million, outside permanent shareholders’ equity. Management said the revision did not change total assets, liabilities, or operating results. It also revised loss-per-share allocation between Class A and Class B shares.
- On October 4, 2021, after quarter-end, Helix announced a business combination agreement with MoonLake Immunotherapeutics AG. Helix expected the transaction to close in late Q4 2021 or early Q1 2022, subject to shareholder approvals and other closing conditions. At closing, Helix was to change its name to MoonLake Immunotherapeutics.
- Concurrent subscription agreements contemplated a $115 million PIPE at $10 per share, conditioned on the business combination closing. This was a proposed transaction, not a completed financing as of the reporting date.
- Helix had until 24 months after its October 22, 2020 IPO closing—October 22, 2022—to complete a business combination or return trust funds to public shareholders, subject to stated terms. The filing separately says the mandatory-liquidation date raises substantial doubt about going concern and refers to November 12, 2022; these dates do not align clearly.
Risks, contingencies, and controls
- Management stated that failure to complete a business combination by the applicable deadline would require Helix to cease operations and liquidate. It identified substantial doubt about the company’s ability to continue as a going concern in that circumstance.
- Helix warned that negative interest rates or a decline in trust assets could reduce public shareholders’ redemption proceeds below $10 per share. COVID-19 could adversely affect its financial position or target search, but the impact was not determinable.
- The Sponsor’s $10,000 monthly administrative-services fee and the $4.025 million deferred underwriting fee are notable obligations. The deferred fee is payable only upon completion of a business combination.
- Helix reported no legal proceedings and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective at a reasonable assurance level and reported no material quarterly change in internal control over financial reporting.
Investor verification priorities
- Confirm the identity and scope of the filing: this is Helix’s pre-combination 10-Q, not MoonLake’s operating-company financial report.
- Verify the business-combination and PIPE closing status, final terms, shareholder approvals, and any changes to the anticipated timing or proceeds.
- Reconcile the October 22, 2022 combination deadline with the filing’s November 12, 2022 going-concern reference.
- Review the redeemable-share accounting revision and confirm how temporary equity and per-share loss allocation are presented in subsequent filings.
- Assess available cash outside the trust, accrued expenses, transaction costs, and whether additional financing was needed to complete the transaction.